Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP-385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP-458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP-150 for treatment of post-traumatic stress disorder. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc . The company was founded in 2003 and is headquartered in Dublin, Ireland.
IPO Year: 2007
Exchange: NASDAQ
Website: jazzpharma.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
6/5/2024 | $169.00 | Buy | Goldman |
1/3/2024 | $160.00 | Outperform | Robert W. Baird |
11/27/2023 | $170.00 → $135.00 | Buy → Neutral | UBS |
9/29/2023 | Mkt Perform | Raymond James | |
6/12/2023 | $184.00 → $140.00 | Equal Weight | Wells Fargo |
12/9/2022 | $192.00 → $190.00 | Neutral → Buy | Goldman |
6/14/2022 | $194.00 | Buy | UBS |
4/6/2022 | $202.00 → $196.00 | Buy → Neutral | Goldman |
3/3/2022 | $210.00 → $215.00 | Buy | HC Wainwright & Co. |
3/2/2022 | $209.00 → $197.00 | Overweight | Piper Sandler |
New and updated data from an ongoing Phase 2 trial of zanidatamab, an investigational dual HER2-targeted bispecific antibody, in combination with chemotherapy for first-line treatment of HER2-positive metastatic gastroesophageal adenocarcinoma (mGEA) DUBLIN, Sept. 9, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the Company, along with its partners, will present five abstracts at the European Society for Medical Oncology (ESMO) Congress 2024 from September 13-17, 2024, in Barcelona, Spain. Presentations include data from trials of zanidatamab and Zepzelca® (lurbinectedin). New and updated data with longer follow-up, including overall survival findings, wil
Data from eight abstracts to be presented, including results of the BECOME (BEhavior, COgnition and More with Epidyolex®) Caregiver Survey on the real-world outcomes of Epidyolex® (cannabidiol) treatment on patients with Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS) DUBLIN, Sept. 5, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the Company will present eight abstracts at the 15th European Epilepsy Congress (EEC), including a subgroup analysis of the BECOME (BEhavior, COgnition and More with Epidyolex®) Caregiver Survey, a survey of caregivers of patients with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) reporting outcomes in patients rece
DUBLIN, Sept. 4, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ("Jazz Pharmaceuticals") today announced the pricing of $850 million aggregate principal amount of 3.125% exchangeable senior notes due 2030 (the "notes") in a private offering (the "offering") by Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The Issuer also granted the initial purchasers of the notes an option, exercisable within a period of 13 days from and including the date the notes are first issued, to purchase up to an additional $150 million aggregate principa
DUBLIN, Sept. 3, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ("Jazz Pharmaceuticals") today announced that Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), intends to offer, subject to market conditions and other factors, $850 million aggregate principal amount of exchangeable senior notes due 2030 (the "notes") in a private offering (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The Issuer also expects to grant the initial purchasers of the notes an option, exercisable within a period of 13 days from and including the date the notes are first issued, to purch
DUBLIN, Aug. 22, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced top-line results from the Phase 3 open-label, single-arm trial in Japan evaluating the safety and efficacy of cannabidiol oral solution (marketed as Epidiolex®/Epidyolex® globally) as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS) or tuberous sclerosis complex (TSC). The trial did not meet the primary efficacy endpoint of a pre-specified percentage change in indication-associated seizure frequency during the treatment period (up to 16 weeks) compared to baseline in Japanese pediatric patients; however, numeric improvements were observed in the
DUBLIN, Aug. 21, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that Company management will participate in the following investor conferences: Wells Fargo Healthcare Conference on Wednesday, September 4, 2024 Fireside chat at 7:15 a.m. PT / 10:15 a.m. ET / 3:15 p.m. ISTBank of America Global Healthcare Conference on Wednesday, September 18, 2024 Fireside chat at 7:55 a.m. PT / 10:55 a.m. ET / 3:55 p.m. ISTAudio webcasts of the fireside chats will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. A replay of the webcasts will be archived on the website for 30 days. About J
– 15% year-over-year revenue increase from combined key growth drivers: Xywav®, Epidiolex® and Rylaze® –– Oncology revenues grew 10% year-over-year –– Zanidatamab granted Priority Review by U.S. FDA for 2L BTC; PDUFA date of November 29, 2024 –– Near-term, late-stage pipeline catalysts anticipated through 2025 –– Narrowing 2024 total revenue guidance to $4.0 to $4.1 billion –– Affirming GAAP and non-GAAP adjusted net income guidance – DUBLIN, July 31, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced financial results for the second quarter of 2024 and updated guidance for 2024. "Jazz's record revenues of over $1 billion in the second quarter were driven by strong e
Ms. Hamill brings extensive experience and proven leadership focused on commercial growth and shareholder value DUBLIN, July 25, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced the election of a new independent director, Laura Hamill, to its Board of Directors. Ms. Hamill, a 35-year veteran of the pharmaceutical industry brings broad executive leadership and global commercial operations expertise to the company's Board. Ms. Hamill's election follows the appointment of Patrick Kennedy earlier this year and reflects Jazz's continued focus on Board renewal. At the Annual General meeting held today, shareholders not only elected Ms. Hamill and Mr. Kennedy but also re-
DUBLIN, July 22, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ("Jazz Pharmaceuticals") today announced that it has completed a repricing of the approximately $2.7 billion outstanding balance of its U.S. dollar term loans under its credit facility. The applicable margin above Term SOFR will be reduced by 75 basis points (from 300 basis points to 225 basis points) and the credit spread adjustment will be removed, resulting in anticipated interest savings of approximately $23 million on an annualized basis. All other terms are substantially unchanged. Irrevocable Election of Settlement Method for the 2.000% Exchangeable Senior Notes due 2026 Jazz Investments I Limited (the "Issue
DUBLIN, July 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that it will report its 2024 second quarter financial results on Wednesday, July 31, 2024, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2024 second quarter financial results and provide a business and financial update. Audio webcast/conference call: U.S. Dial-In Number: +1 800 715 9871Ireland Dial-In Number: +353 1800 943 926Additional global dial-in numbers are available here.Passcode: 9124647 Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals websi
For Immediate Release: August 12, 2021 The U.S. Food and Drug Administration today approved a new indication for Xywav for idiopathic hypersomnia (IH) in adults. IH is an uncommon chronic sleep disorder that causes people to be excessively sleepy during the day even after a good night's sleep. Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution is already approved for the treatment of catapl
Ms. Hamill brings extensive experience and proven leadership focused on commercial growth and shareholder value DUBLIN, July 25, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced the election of a new independent director, Laura Hamill, to its Board of Directors. Ms. Hamill, a 35-year veteran of the pharmaceutical industry brings broad executive leadership and global commercial operations expertise to the company's Board. Ms. Hamill's election follows the appointment of Patrick Kennedy earlier this year and reflects Jazz's continued focus on Board renewal. At the Annual General meeting held today, shareholders not only elected Ms. Hamill and Mr. Kennedy but also re-
NodThera INC ("NodThera" or the "Company") NodThera Announces Appointment of Daniel Swisher as Chief Executive Officer Dan joins NodThera with over 30 years of pharmaceutical industry leadership experience, including as President and COO of Jazz Pharmaceuticals and CEO of Sunesis PharmaceuticalsInterim CEO Alan Watt becomes President and CSO including leadership of R&D to further build out NodThera's pioneering work in CNS modulation of chronic inflammatory diseases BOSTON, MA, May 28, 2024 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces the a
Mr. Kennedy brings wealth of experience managing high growth organizations focused on creating value for shareholders DUBLIN, Feb. 27, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced the appointment of a new independent director, Patrick Kennedy, to its Board of Directors. Mr. Kennedy, Chair and Governor of the Bank of Ireland, has been appointed to the Jazz Board and will serve on the Audit Committee effective March 1, 2024. Peter Gray has decided not to seek re-election to the Jazz Board at the next Annual General Meeting, expected in July 2024. Mr. Kennedy's appointment reflects Jazz's ongoing focus on Board renewal, and his financial and operating expertise wi
Mr. Johnson Brings Over 35 Years of Financial and Operating Experience to Leadership Team DUBLIN, Feb. 21, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ("Jazz" or the "Company") today announced that Philip Johnson has been appointed Executive Vice President and Chief Financial Officer, effective March 1, 2024. Mr. Johnson succeeds Renée Galá, who was promoted to President and Chief Operating Officer in October 2023. Mr. Johnson joins Jazz Pharmaceuticals with over 35 years of financial experience, most recently leading Eli Lilly and Company's treasury and investor relations operations as Group Vice President of Finance. In his new role, Mr. Johnson will oversee financial repo
PRINCETON, N.J., April 05, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced the appointment of an additional member to its Board of Directors. Effective immediately, George Eliades, Ph.D, current Senior Vice President, Corporate Development and Chief Transformation Officer of Jazz Pharmaceuticals (Nasdaq: JAZZ), will join Oyster Point’s Board of Directors and serve as a member of the Compensation Committee. “We are excited to welcome George to our Board of Directors as we
8-K - Jazz Pharmaceuticals plc (0001232524) (Filer)
8-K - Jazz Pharmaceuticals plc (0001232524) (Filer)
144 - Jazz Pharmaceuticals plc (0001232524) (Subject)
10-Q - Jazz Pharmaceuticals plc (0001232524) (Filer)
8-K - Jazz Pharmaceuticals plc (0001232524) (Filer)
8-K - Jazz Pharmaceuticals plc (0001232524) (Filer)
DEFA14A - Jazz Pharmaceuticals plc (0001232524) (Filer)
8-K - Jazz Pharmaceuticals plc (0001232524) (Filer)
ARS - Jazz Pharmaceuticals plc (0001232524) (Filer)
DEFA14A - Jazz Pharmaceuticals plc (0001232524) (Filer)
4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
Goldman initiated coverage of Jazz Pharma with a rating of Buy and set a new price target of $169.00
Robert W. Baird initiated coverage of Jazz Pharma with a rating of Outperform and set a new price target of $160.00
UBS downgraded Jazz Pharma from Buy to Neutral and set a new price target of $135.00 from $170.00 previously
Raymond James initiated coverage of Jazz Pharma with a rating of Mkt Perform
Wells Fargo resumed coverage of Jazz Pharma with a rating of Equal Weight and set a new price target of $140.00 from $184.00 previously
Goldman upgraded Jazz Pharma from Neutral to Buy and set a new price target of $190.00 from $192.00 previously
UBS initiated coverage of Jazz Pharma with a rating of Buy and set a new price target of $194.00
Goldman downgraded Jazz Pharma from Buy to Neutral and set a new price target of $196.00 from $202.00 previously
HC Wainwright & Co. reiterated coverage of Jazz Pharmaceuticals with a rating of Buy and set a new price target of $215.00 from $210.00 previously
Piper Sandler reiterated coverage of Jazz Pharmaceuticals with a rating of Overweight and set a new price target of $197.00 from $209.00 previously
SC 13G/A - Jazz Pharmaceuticals plc (0001232524) (Subject)
SC 13G/A - Jazz Pharmaceuticals plc (0001232524) (Subject)
SC 13G/A - Jazz Pharmaceuticals plc (0001232524) (Subject)
SC 13G/A - Jazz Pharmaceuticals plc (0001232524) (Subject)
SC 13G/A - Jazz Pharmaceuticals plc (0001232524) (Subject)
SC 13G/A - Jazz Pharmaceuticals plc (0001232524) (Subject)
SC 13G - Jazz Pharmaceuticals plc (0001232524) (Subject)
SC 13G/A - Jazz Pharmaceuticals plc (0001232524) (Subject)
SC 13G/A - Jazz Pharmaceuticals plc (0001232524) (Subject)
SC 13G - Jazz Pharmaceuticals plc (0001232524) (Subject)
– 15% year-over-year revenue increase from combined key growth drivers: Xywav®, Epidiolex® and Rylaze® –– Oncology revenues grew 10% year-over-year –– Zanidatamab granted Priority Review by U.S. FDA for 2L BTC; PDUFA date of November 29, 2024 –– Near-term, late-stage pipeline catalysts anticipated through 2025 –– Narrowing 2024 total revenue guidance to $4.0 to $4.1 billion –– Affirming GAAP and non-GAAP adjusted net income guidance – DUBLIN, July 31, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced financial results for the second quarter of 2024 and updated guidance for 2024. "Jazz's record revenues of over $1 billion in the second quarter were driven by strong e
DUBLIN, July 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that it will report its 2024 second quarter financial results on Wednesday, July 31, 2024, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2024 second quarter financial results and provide a business and financial update. Audio webcast/conference call: U.S. Dial-In Number: +1 800 715 9871Ireland Dial-In Number: +353 1800 943 926Additional global dial-in numbers are available here.Passcode: 9124647 Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals websi
Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2024, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We are pleased to report another quarter of strong financial results driven by the performance of our commercial royalty portfolio. Simultaneously, we continue to build our portfolio of development stage royalty assets to deliver future growth," said Todd Davis, CEO of Ligand. "We continue to originate a robust pipe
– 12% year-over-year revenue increase from combined key growth drivers: Xywav®, Epidiolex® and Rylaze® –– Oncology revenues grew 13% year-over-year –– Submitted zanidatamab BLA for 2L BTC; expect to launch in 2025 or earlier –– Top-line Phase 2b data from suvecaltamide trial in essential tremor expected in late 1H24 –– 2024 total revenue guidance affirmed at $4.0 to $4.2 billion – DUBLIN, May 1, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced financial results for the first quarter of 2024 and affirmed guidance for 2024. "In the first quarter of 2024, we delivered combined double-digit year-over-year growth from our key growth drivers: Xywav, Epidiolex and Rylaze.
DUBLIN, April 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that it will report its 2024 first quarter financial results on Wednesday, May 1, 2024, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2024 first quarter financial results and provide a business and financial update. Audio webcast/conference call: U.S. Dial-In Number: +1 800 715 9871Ireland Dial-In Number: +353 1800 943 926Additional global dial-in numbers are available here.Passcode: 8991966 Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website
DUBLIN, March 12, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) will host a virtual R&D Day, Tuesday, March 19, from 8:00 a.m. to 10:00 a.m. ET, focused on zanidatamab, a differentiated, bispecific antibody in late-stage development with the potential to transform the standard of care in multiple HER2-positive cancers. The webcast will highlight the mechanistic rationale and clinical data that support further development of zanidatamab as a treatment for biliary tract cancer (BTC), gastroesophageal adenocarcinoma (GEA) and breast cancer. External key opinion leaders in GEA and breast cancer will also discuss current treatment paradigms and unmet needs for those cancers, and how
– Total revenues of $3.8 billion in 2023 and $1 billion in 4Q23 –– 27% year-over-year revenue increase from combined key growth drivers: Xywav®, Epidiolex® and Rylaze® –– Oncology revenue surpassed $1 billion in 2023 –– Multiple late-stage pipeline catalysts anticipated in 2024 –– 2024 total revenue guidance reflects continued top-line growth – DUBLIN, Feb. 28, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced financial results for the full year and fourth quarter of 2023 and provided guidance for 2024. "2023 was a year of continued strong execution that delivered top- and bottom-line growth and over $3.8 billion in total revenue. Sleep1 revenue exceeded $1.9 billio
DUBLIN, Feb. 14, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that it will report its 2023 full year and fourth quarter financial results on Wednesday, February 28, 2024, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. GMT to discuss 2023 full year and fourth quarter financial results and provide a business and financial update. Audio webcast/conference call: U.S. Dial-In Number: +1 888 350 4423Ireland Dial-In Number: +353 1800 943 926Additional global dial-in numbers are available here.Passcode: 6907242 Interested parties may access the live audio webcast via the Investors section of
Raising 2023 Guidance Investor and Analyst Day to be held on Tuesday December 12th in New York City Conference call begins at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We're pleased to report another quarter of strong financial results and we are now actively executing on our investment strategy as evidenced by the recent Tolerance, Ovid, Novan and Primrose transact
– Strong execution delivered second quarter 2023 total revenues of $957 million –– Commercial excellence drove continued adoption of low-sodium Xywav®; net product sales increased 39% year-over-year –– Continued growth of Epidiolex®; net product sales increased 15% 2Q23 year-over-year –– Strong demand for Rylaze® drove 39% increase in net product sales year-over-year –– Oncology portfolio expected to reach ~$1 billion in net product sales this year –– Zanidatamab leads a diversified pipeline with near-term catalysts positioned to deliver as many as four late-stage data readouts by the end of 2024 – DUBLIN, Aug. 9, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced fi
4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
Jazz Pharmaceuticals's (NYSE:JAZZ) short percent of float has risen 4.88% since its last report. The company recently reported that it has 2.68 million shares sold short, which is 5.59% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.93 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short in
Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Equal-Weight and lowers the price target from $160 to $150.
The U.S. Federal Trade Commission (FTC) recently highlighted the significant influence of pharmacy benefit managers (PBMs) on drug prices due to market consolidation. This trend raises critical questions about the future of the cannabis industry, especially if cannabis is federally legalized. The Role Of PBMs And Market Influence PBMs, such as UnitedHealth Group (NYSE:UNH)'s Optum, CVS Health (NYSE:CVS)'s CVS Caremark and Cigna (NYSE:CI)'s Express Scripts, negotiate discounts, create medication lists covered by insurance and reimburse pharmacies. The FTC's interim report revealed that these three PBMs manage 79% of U.S. prescription drug claims, consolidating their power and impacting dru
Cannabinoid-focused biopharmaceutical company Avicanna Inc. (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN) announced on Thursday that it has completed the commercial export of Aureus-branded purified cannabigerol (CBG) products into Singapore through its majority-owned subsidiary Santa Marta Golden Hemp. The company said that, with this transaction – its first export into Asia, Aureus-branded products have now reached 18 international markets. Avicanna products are now available in 21 markets. Cannabis Is Still Stigmatized And Illegal Meanwhile, in Singapore, cannabis remains stigmatized. The Central Narcotics Bureau of Singapore is of the stance that cannabis should be considered an illicit d
In the last three months, 7 analysts have published ratings on Jazz Pharmaceuticals (NASDAQ:JAZZ), offering a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 2 1 0 0 Last 30D 0 0 1 0 0 1M Ago 2 0 0 0 0 2M Ago 1 1 0 0 0 3M Ago 1 1 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Jazz Pharmaceuticals, presenting an average target of $184.86, a high estimate of $222.00, and a low estimate of $113.00. Experienci
UBS analyst Ashwani Verma maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Neutral and lowers the price target from $117 to $113.
Thursday, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) released topline results from the Phase 2b trial evaluating the efficacy and safety of suvecaltamide (JZP385), an investigational, highly selective and state-dependent modulator of T-type calcium channels, in adult patients with essential tremor (ET). The Phase 2b study assessed the efficacy and safety of suvecaltamide in a once-daily oral dose of 10, 20, and 30mg or placebo. Suvecaltamide did not achieve statistical significance at 30mg versus placebo on the primary endpoint of change from baseline to week 12 on the Essential Tremor Rating Assessment Scale (TETRAS) modified composite outcome score and key secondary endpoint of Clinical
Needham analyst Ami Fadia maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and lowers the price target from $222 to $210.
The trial also did not meet On Key Secondary Endpoint Of Clinical Global Impression-severity Scale
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Guggenheim analyst Subbu Nambi initiated coverage on Twist Bioscience Corporation (NASDAQ:TWST) with a Buy rating, while announcing a price target of $53. Twist Bioscience shares gained 6.8% to close at $46.98 on Tuesday. See how other analysts view this stock. BMO Capital analyst Fadi Chamoun initiated coverage on Old Dominion Freight Line, Inc. (NASDAQ:ODFL) with an Outperform rating and announced a price target of $210. Old Dominion Freight Line shares rose 1.7% to settle at $172.14